Launch of VivaGel condoms delayed in Japan
05 December, 2014 by Dylan Bushell-EmblingStarpharma (ASX:SPL) and partner Okamoto Industries have had to delay the launch of their VivaGel condoms in Japan for at least 3-6 months pending a regulatory classification review.
Project aims to improve pharma manufacturing efficiency
05 December, 2014 by Dylan Bushell-EmblingCSL (ASX:CSL), Hospira and GlaxoSmithKline have partnered with META and the University of Melbourne for a project aimed at improving manufacturing efficiency at Australian sites.
Boosting commercial returns from research
04 December, 2014AusBiotech has made a submission to the federal government's consultation regarding 'Boosting commercial returns from research', as part of the Industry Innovation and Competitiveness Agenda.
Rhinomed's Mute approved by TGA, FDA, EMA
04 December, 2014 by Dylan Bushell-EmblingRhinomed (ASX:RNO) has won approval from key regulators for Mute, a medical device for snoring and sleep breathing, and published top-line data from a trial of the product in snorers.
VivaGel condoms cleared for sale in NZ: Starpharma
02 December, 2014 by Dylan Bushell-EmblingStarpharma and partner Ansell have won regulatory approval to market the LifeStyles Dual Protect condoms in New Zealand.
Let the partnering begin! Biotech investment takes centre stage at Australia Biotech Invest 2014
02 December, 2014Two days of intensive discussion at Australia Biotech Invest 2014 will commence tomorrow to highlight the innovation and positive momentum happening in the Australian life sciences sector.
Circadian closes $17.4m capital raising
01 December, 2014 by Dylan Bushell-EmblingCircadian Technologies (ASX:CIR) has raised $17.4m through a placement and share purchase plan, and plans to use the proceeds to take OPT-302 into the clinic in wet AMD.
GID resumes EndoBarrier shipments in EU
01 December, 2014 by Dylan Bushell-EmblingGI Dynamics (ASX:GID) has received the all-clear to resume shipments of its EnBobarrier obesity and diabetes therapy in the EU following a two-month suspension.
TGA approval for antioxidant
28 November, 2014Riding on the strength of a clinical trial that showed glutathione boosts immune function, Trans Chem has launched Setria Glutathione to the Australian market.
Industry launches AIM Incentive policy paper in Canberra
27 November, 2014AusBiotech and Australian industry leaders presented the Australian Innovation & Manufacturing (AIM) Incentive to members and senators at Parliament in Canberra this morning, declaring the model a 'good' patent box solution that would boost Australia's manufacturing industry and international competitiveness.
Phylogica secures EU patent for Phylomer libraries
26 November, 2014 by Dylan Bushell-EmblingPhylogica (ASX:PYC) has received a notice of allowance for an EU patent covering its synthetic Phylomer libraries, which have applications in biosensors and personalised medicine.
STA wins TGA approval for Iclusig in leukaemia
26 November, 2014 by Dylan Bushell-EmblingSpecialised Therapeutics Australia has secured TGA approval for ARIAD Pharmaceuticals' Iclusig in two types of leukaemia.
New report on medtech industry's global performance
25 November, 2014EY has released its annual medical technology report for 2014 - 'Pulse of the industry: differentiating differently'.
Calzada to divest its Metabolic subsidiary
24 November, 2014 by Dylan Bushell-EmblingCalzada (ASX:CZD) plans to pursue a sale or spin-off of its Metabolic Pharmaceuticals subsidiary to hand over responsibilities for funding the development of peptide fragment AOD9604.
Paradigm BioPharmaceuticals launches $13.5m IPO
24 November, 2014 by Dylan Bushell-EmblingMelbourne's Paradigm BioPharmaceuticals will raise up to $13.5m via an ASX IPO to help raise funds for trials of legacy drug PPS as a treatment for bone marrow edema (BME).
